News
AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...
In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...
Zacks.com on MSN12h
PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...
In August 2025, Seagen announced a studies how well tucatinib works for solid tumors that make either more HER2 or a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback